System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 4 citations

PubMed: 40640916 DOI: 10.1186/s12987-025-00688-z

Restoring brain barriers: an innovative approach for treating neurological disorders.

Fluids Barriers CNS 22(1):72

Authors: Sighild Lemarchant, Britta Engelhardt, Francesca Cicchetti, Gregory J Bix, Annette Janus, Yann Godfrin, Hélène Blasco, Matthew Campbell, Aurélie de Rus Jacquet

Affiliations

  • Axoltis Pharma, Lyon, 69008, France.
  • Theodor Kocher Institute, University of Bern, Bern, 3012, Switzerland.
  • Centre de Recherche du CHU de Québec, Université Laval, Axe Neurosciences, Québec, QC, G1V 4G2, Canada.
  • Department of Psychiatry and Neurosciences, Faculty of Medicine, Université Laval, Québec, QC, G1V 0A6, Canada.
  • Department of Neurosurgery, Clinical Neuroscience Research Center, Tulane University School of Medicine, New Orleans, LA, USA.
  • Tulane Brain Institute, Tulane University, New Orleans, LA, USA.
  • Department of Neurology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA.
  • Axoltis Pharma, Lyon, 69008, France.
  • UMR 1253 iBrain, Université de Tours, Inserm, Tours, 37000, France.
  • Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland.
  • Centre de Recherche du CHU de Québec, Université Laval, Axe Neurosciences, Québec, QC, G1V 4G2, Canada. Department of Psychiatry and Neurosciences, Faculty of Medicine, Université Laval, Québec, QC, G1V 0A6, Canada.

Abstract

The complex etiology of neurological disorders is a major challenge to the identification of therapeutic candidates. Tackling brain vascular dysfunction is gaining attention from the scientific community, neurologists and pharmaceutical companies, as a novel disease-modifying strategy. Here, we provide evidence that at least 41% of neurological diseases and related conditions/injuries display a co-pathology of blood-brain and blood-spinal cord barrier alterations and dysfunctions, and we discuss why this figure may represent only a fraction of a larger phenomenon. We further provide clinical evidence that barrier status may contribute to pathological and functional outcomes in patients. Finally, we discuss drug candidates under development to repair brain barriers.

MeSH

Blood, Pharmaceutical Preparations, Brain, Nervous System Diseases